ImmunoGen

Iksuda Therapeutics and Femtogenix Sign License Agreement

Retrieved on: 
Tuesday, March 5, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Medical Supplies, Medical specialties, Medicine, Immunology, Branches of biology, ADC, Antibody, Synaffix, Antibody-drug conjugates, Monoclonal antibodies, ImmunoGen

Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.

Key Points: 
  • Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.
  • As part of this agreement, Iksuda will use FGXs sequence-selective DNA-interactive payload molecules to progress its lead ADC towards the clinic, with the aim of targeting difficult-to-treat solid tumours.
  • The agreement marks another key step in the build-out of Iksudas ADC technology-suite and drug pipeline, from which it aims to progress multiple candidates towards first clinical studies in 2020.
  • In particular, we are developing payloads that can recognise and bind to transcription factor recognition site profiles within the genome.

ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

Retrieved on: 
Wednesday, February 27, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, ImmunoGen, Linker

ImmunoGen remains at the forefront of ADC innovation and the data to be presented at AACR further demonstrate the value of our productive research platform, said Richard Gregory, Ph.D., ImmunoGens chief scientific officer.

Key Points: 
  • ImmunoGen remains at the forefront of ADC innovation and the data to be presented at AACR further demonstrate the value of our productive research platform, said Richard Gregory, Ph.D., ImmunoGens chief scientific officer.
  • Both mono-and-di-imine IGN molecules remained bound to genomic DNA even at two days, suggesting a potent interaction with cellular DNA.
  • Several dipeptide linker designs were superior in rates of lysosomal processing compared to a reference standard L-Ala-L-Ala dipeptide linker.
  • DM51 (the thiol- resulting from self-immolation of the cleaved linker-payload) was identified as a major catabolite of the DM21-C ADC.

Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, February 19, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, ImmunoGen

Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors.

Key Points: 
  • Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors.
  • "We are excited to start clinical development of a new generation of radiopharmaceuticals utilizing our Fast-ClearTM Linker to address the need for better cancer treatments.
  • The Phase 1 clinical study (FPX-01-01) is a dose-escalation study that will characterize the safety and tolerability of a single dose [225Ac]-FPI-1434 Injection in patients with advanced solid tumors.
  • Fusion has an exclusive license to AVE1642 from ImmunoGen, Inc. Fusion applied its Fast-ClearTM linker to convert AVE1642 into a potent radiopharmaceutical, [225Ac]-FPI-1434.

ImmunoGen Reports Recent Progress and 2018 Operating Results

Retrieved on: 
Friday, February 8, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Medicine, Medical specialties, Immunology, Clinical medicine, ImmunoGen, Antibody-drug conjugate

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress and operating results for the quarter and year ended December 31, 2018.

Key Points: 
  • ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress and operating results for the quarter and year ended December 31, 2018.
  • Operating expenses for 2018 were $214.3 million, compared with $174.4 million for 2017.
  • Cash used in operations was $166.4 million for 2018, compared with cash provided from operations of $7.6 million for 2017.
  • ImmunoGen will hold a conference call today at 8:00 am ET to discuss these results.

ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

Retrieved on: 
Thursday, January 24, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Medicine, Cancer treatments, Clinical medicine, Immunology, Antineoplastic drugs, Antibody-drug conjugate, Biotechnology, ImmunoGen

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at8:00 a.m. ETonFriday, February 8, 2019to discuss its 2018 operating results.

Key Points: 
  • ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at8:00 a.m. ETonFriday, February 8, 2019to discuss its 2018 operating results.
  • To access the live call by phone, dial 323-794-2093; the conference ID is 6271602.
  • The call may also be accessed through the Investors section of the Companys website, www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

ImmunoGen Announces Sale of Residual Kadcyla Royalties

Retrieved on: 
Tuesday, January 8, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Immunology, ImmunoGen, Royalty payment, Trastuzumab emtansine, Medicine, Health

This transaction entails the sale of the residual interest held by ImmunoGen from a prior transaction with Immunity Royalty Holdings, L.P. (IRH).

Key Points: 
  • This transaction entails the sale of the residual interest held by ImmunoGen from a prior transaction with Immunity Royalty Holdings, L.P. (IRH).
  • In 2015, ImmunoGen announced a $200 million non-dilutive royalty transaction through which ImmunoGen sold the right to receive 100% of the royalty revenue on Kadcyla commercial sales to an undisclosed threshold amount, subject to certain conditions.
  • This agreement entitles ImmunoGen to receive royalties ranging from 3-5% on Kadcyla sales in countries where ImmunoGen holds valid patents covering Kadcyla, and 2% in countries without relevant ImmunoGen patents.
  • ImmunoGen is entitled to receive royalties on commercial Kadcyla sales in each country for ten years after the launch of Kadcyla in that country.

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076

Retrieved on: 
Friday, December 21, 2018
Medicine, Immunology, Immune system, Health, ImmunoGen, Antigen, Antibody, Maytansinoid

"We also aim to develop OBT076 for other solid tumors expressing the target antigen.

Key Points: 
  • "We also aim to develop OBT076 for other solid tumors expressing the target antigen.
  • OBT Chief Executive Officer, Dr. Christian Rohlff said, "The FDA's acceptance of the IND for OBT076 is an important milestone in OBT's US product development strategy.
  • OBT076, is an antibody drug conjugate (ADC) comprising a fully human antibody targeting CD205, coupled to the DM4 toxin from Immunogen.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com